Aeson® artificial heart presented at a web conference organized by Ladenburg Thalmann

Paris, October 21, 2021 – 6:00 pm CEST

                    
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announced today that Ladenburg Thalmann, a leading U.S. investment bank, hosted a web conference on October 20, 2021 on the Aeson^® artificial heart, with the participation of surgeons from Duke University Hospital and the Jewish Hospital of Louisville who have performed the first Aeson^® implants in the United States in recent months as part of the Early Feasibility Study (EFS).
 
Speakers at the conference included:

• Stéphane Piat, Chief Executive Officer of CARMAT;
• Dr. Piet Jansen, Chief Medical Officer of CARMAT;
• Dr. Carmelo Milano, cardiac surgeon at Duke University Hospital;
• Dr. Mark Slaughter, cardiac surgeon at UofL Health – Jewish Hospital & University of Louisville. 

You can access the replay of this web conference by clicking on this link.     

• Download the file